Form 4: Generation Bio Director Sells Shares Post-Merger

Generation Bio Co. director Dannielle Appelhans reported the disposition of common stock and stock options following the company's merger with XOMA Royalty Corporation's subsidiary.

Summary

• Generation Bio Co. (GBIO) has completed its merger with XRA 7 Corp., a wholly-owned subsidiary of XOMA Royalty Corporation, effective February 9, 2026.
• As a result of the merger, each share of Generation Bio common stock was exchanged for a cash amount of $4.2913 and one non-tradeable contingent value right (CVR).
• The CVR represents the right to receive certain contingent payments in cash, with an estimated maximum contingent consideration of $25.01 per CVR.
• Dannielle Appelhans, a Director of Generation Bio Co., disposed of 1,263 shares of common stock directly and 736 shares indirectly (by spouse) on February 9, 2026.
• Stock options with an exercise price less than the cash amount ($4.2913) became fully vested, were cancelled, and converted into a cash payment equal to the difference between the cash amount and the exercise price, multiplied by the number of shares.
• Stock options with an exercise price equal to or greater than the cash amount were automatically cancelled for no consideration.
• Appelhans disposed of 3,000 in-the-money stock options with an exercise price of $3.874.
• Appelhans also disposed of 3,840 stock options with an exercise price of $71.8, 2,500 stock options with an exercise price of $48.3, and 6,000 stock options with an exercise price of $33.2, all of which were out-of-the-money and cancelled for no consideration.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as a procedural report confirming the successful completion of a merger, which provided former Generation Bio Co. shareholders with a cash payment and a contingent value right, effectively concluding the company's public trading.

Positives

• The merger provided Generation Bio Co. stockholders with immediate cash consideration of $4.2913 per share.
• Stockholders also received a Contingent Value Right (CVR) per share, offering potential future cash payments with an estimated maximum of $25.01 per CVR.
• In-the-money stock options were converted into cash payments, providing value to option holders.

Negatives

• Stock options with an exercise price equal to or greater than the cash amount ($4.2913) were cancelled for no consideration, resulting in a loss of value for those option holders.
• Generation Bio Co. is no longer an independent publicly traded company, becoming a wholly-owned subsidiary of XOMA Royalty Corporation.

Risks

• The contingent value right (CVR) has an 'estimated maximum contingent consideration amount of $25.01 per CVR,' indicating that the actual contingent payments could be less than this maximum.

Future Outlook

The filing indicates that Generation Bio Co. is now a wholly-owned subsidiary, and its common stock is no longer publicly traded. The future outlook for former shareholders is tied to the contingent payments from the CVRs, which are subject to specific conditions outlined in a separate agreement.

Industry Context

StockSavvy.ai notes this filing represents the final stages of a typical acquisition process in the biotechnology sector. The use of a Contingent Value Right (CVR) is a common mechanism in biotech mergers to bridge valuation gaps, especially when a significant portion of the target company's value is tied to future clinical or regulatory milestones. This structure allows the acquiring company to mitigate risk while offering potential upside to the selling shareholders.

Comparison to Industry Standards

• The use of a Contingent Value Right (CVR) in the merger consideration is a common practice in the biotechnology and pharmaceutical industries, particularly when valuing pipeline assets or future milestones that carry inherent development and regulatory risks. This structure allows the acquiring company to defer a portion of the purchase price and tie it to the achievement of specific future events, while providing selling shareholders with potential upside beyond the initial cash payment. Specific comparable companies or projects are not detailed in this filing, but such structures have been seen in acquisitions like Celgene's acquisition of Juno Therapeutics or Sanofi's acquisition of Synthorx, where CVRs were used to bridge valuation gaps related to clinical development or regulatory approvals.

Corporate Governance

Stakeholder Impact

• Shareholders of Generation Bio Co. received a cash payment and a Contingent Value Right (CVR) for their shares, concluding their direct equity ownership in the company.
• Employees of Generation Bio Co. are now part of a wholly-owned subsidiary of XOMA Royalty Corporation.

Next Steps

• Contingent payments to CVR holders will be made in cash in accordance with the terms and conditions of the contingent value rights agreement.

Key Dates

Keywords

Generation Bio, GBIO, XOMA Royalty Corporation, Merger, Acquisition, Form 4, Insider Transaction, Stock Options, Contingent Value Right, Biotechnology